SCHEMBL24435010

SCHEMBL24435010

CC(C)(COc1ccccc1Br)c1csc(NC(=O)c2cccn2Cc2ccncc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
SCN3A Q9NY46 4/20 0.40
RAB9A P51151 6/20 0.40
NPC1 O15118 5/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPK1 P28482 4/20 0.40
LMNA P02545 3/20 0.40
HPGD P15428 3/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 2/20 0.40
TSHR P16473 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31466426 1.00 SMN1; SMN2 (0.41) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24435009 0.88 SCN3A (0.44) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24435208 0.87 NPC1 (0.45) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24434537 0.82 SMN1; SMN2 (0.60) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24435182 0.81 CYP1A2 (0.47) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24434977 0.81 SMN1; SMN2 (0.49) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24435153 0.80 MEN1 (0.43) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24435076 0.80 MEN1 (0.48) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24434894 0.79 SCN3A (0.45) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A
SCHEMBL24434983 0.79 SMN1; SMN2 (0.44) SMN1; SMN2TAS1R3TAS1R1TAS1R2SCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G SMN1; SMN2 4057/4885TAS1R3 1915/4885TAS1R1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.